港股异动 | 宝济药业-B(02589)逆市涨近5% 公司晟诺娃®此前获批上市 目前已提交KJ017 NDA

智通财经
Dec 16, 2025

智通财经APP获悉,宝济药业-B(02589)逆市涨近5%,截至发稿,涨3.79%,报68.45港元,成交额1837.76万港元。

消息面上,近日,宝济药业-B正式登陆港交所主板,上市首日收涨138.82%,总市值现已突破200亿港元。据宝济药业招股书披露,公司战略性聚焦四大领域:大容量皮下给药,抗体介导的自身免疫性疾病,辅助生殖及重组生物制药。公司的管线主要包括12款自主开发在研产品,包括三款核心产品(KJ017、KJ103及SJ02(晟诺娃®))、四款其他临床阶段候选药物(BJ007、KJ015、SJ04及KJ101)及五款临床前资产(BJ008、BJ009、BJ045、BJ047及BJ044)。

智通财经APP在《“自我造血”的新晋18A,宝济药业-B(02659)以“三驾马车”打造可持续增长样本》中指出,在“场景驱动”的战略选择、合成生物学的技术壁垒以及“总成本领先”的工业化优势的协同下,宝济药业得以形成其独有的“金字塔型”管线布局。其中,作为现金流的根据地,宝济药业的“金字塔型”管线底座,由临床周期短、费用低、市场需求确定性高的产品构成,如已获批上市的SJ02和已提交NDA的KJ017。该类产品由于聚焦解决明确的临床场景痛点和技术替代,能够快速形成稳定的销售和现金流,为企业提供“自我造血”能力,从而有效消除18A企业普遍存在的“融资焦虑”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10